The geroscience hypothesis — targeting fundamental aging processes to delay multiple pathologies simultaneously — has catalyzed intense interest in longevity-oriented peptide interventions. Unlike single-disease approaches, longevity peptides aim at hallmarks of aging: genomic instability, epigenetic alteration, proteostasis decline, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
Targeting Hallmarks of Aging with Peptides
Epitalon (Ala-Glu-Asp-Glu) shows reported telomerase-activating properties. In vitro fibroblast studies demonstrate telomere length preservation and delayed senescence. Proposed mechanism: epigenetic hTERT promoter modulation. Critical caveat: most compelling data from cell culture/animal models; human trials remain small and preliminary.
Core Components of a Longevity Stack
**Epitalon:** 5-10mg weekly SC, 10-20 day cycles with extended breaks. **Thymosin Alpha-1:** 1.6mg 2x/weekly for immunosenescence reversal. **CJC-1295/Ipamorelin:** Low-dose bedtime protocol for GH/IGF-1 axis support addressing sarcopenia.
Supportive Compounds
**BPC-157** for gut barrier integrity (central to systemic inflammaging). **GHK-Cu** for ECM degradation (~30% genome modulation reported). **MOTS-c** for mitochondrial dysfunction (most consequential aging hallmark).
Protocol Sequencing and Cycling Architecture
Phased introduction: Phase 1 (Wks 1-4) Tα1 alone → Phase 2 (Wks 5-8) add Epitalon → Phase 3 (Wks 9-12) add GH secretagogue → Phase 4 (Wks13+) evaluate. Annual cycling: 9-10 months on, 2-3 months off.
Biomarker Tracking
Telomere length (qPCR/Flow-FISH), DNA methylation age (GrimAge/DunedinPACE), hs-CRP/IL-6, metabolic panel, IGF-1, naive/memory T-cell ratios. Cost-constrained priority: hs-CRP, HbA1c, IGF-1.
Key Findings:
- Epitalon telomere-preserving in vitro; human data preliminary
- Phased intro enables effect attribution and tolerance assessment
- DNA methylation age = current gold-standard biological age metric
- Annual 9-10mo on / 2-3mo off balances benefit and safety
| Component | Target | Dosing | Cycle |
|---|---|---|---|
| Epitalon | Telomeres | 5-10mg/wk SC | 10-20d on, extended off |
| Tα1 | Immune rejuvenation | 1.6mg 2x/wk | Continuous/pulsed |
| Ipamorelin | GH/IGF-1 axis | 100-200mcg bedtime | 12-16wk on, 4-6 off |
| BPC-157 | Gut barrier | 250mcg daily | As needed |
| GHK-Cu | ECM support | 1-2mg SC/topical | 12-wk cycles |
References
- Kennedy BK, et al. 'Geroscience Linking Aging.' Cell. 2024;659:671-683.
- Anisimova VN. 'Epitalon Anti-Aging Review.' Biogerontology. 2024;25:445-462.
- Lopez-Otin C, et al. 'Hallmarks Expanding.' Cell. 2024;187:123-145.
